Stocks to Watch: Peregrine Pharmaceuticals, Galena Biopharma Inc, Biogen Idec Inc, Ariad Pharmaceuticals

Lakeway, TX -- (SBWIRE) -- 02/19/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Peregrine Pharmaceuticals (NASDAQ:PPHM) fell 8.16% and is trading at $1.69. Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company developing monoclonal antibodies for the treatment and diagnosis of cancer. The Company's pipeline of investigational monoclonal antibodies is based on two technology platforms, including PS-targeting antibodies and DNA/histone-targeting antibodies.

Is PPHM a Buy After The Latest Announcement? Find out Here

Galena Biopharma Inc (NASDAQ:GALE) is lower 0.82% and is trading at $1.81. Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors.

Is GALE a Buy after the Solid report? Get Special Coverage Here

Biogen Idec Inc. (NASDAQ:BIIB) fell 0.63% and is trading at $167.68. Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN.

How Should Investors Trade BIIB After The Latest Report? Find Out Here

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is higher 0.40% and is trading at $19.92. ARIAD Pharmaceuticals, Inc. (ARIAD) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD’s first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy.

How Should Investors Trade ARIA After The Latest Earnings Report? Find Out Here

About bestdamnpennystocks.com
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.